{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:29:49Z","timestamp":1790530189041,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["anesthesiology.theclinics.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anesthesiology Clinics"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.anclin.2017.01.017","type":"journal-article","created":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T06:45:38Z","timestamp":1492152338000},"page":"e95-e113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["New Hypnotic Drug Development and Pharmacologic Considerations for Clinical Anesthesia"],"prefix":"10.1016","volume":"35","author":[{"given":"Mariah Kincaid","family":"Tanious","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha S.","family":"Beutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Urman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anclin.2017.01.017_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/ALN.0b013e3181ae8460","article-title":"Is anesthesiology going soft?","volume":"111","author":"Egan","year":"2009","journal-title":"Anesthesiology"},{"key":"10.1016\/j.anclin.2017.01.017_bib2","series-title":"Retrometabolic drug design and targeting","first-page":"71","author":"Bodor","year":"2012"},{"issue":"Suppl 1","key":"10.1016\/j.anclin.2017.01.017_bib3","first-page":"S2","article-title":"Anesthetic drug development: novel drugs and new approaches","volume":"4","author":"Chitilian","year":"2013","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.anclin.2017.01.017_bib4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/bja\/aeq190","article-title":"New drugs and technologies, intravenous anaesthesia is on the move (again)","volume":"105","author":"Sneyd","year":"2010","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.anclin.2017.01.017_bib5","unstructured":"Siegel LC, Konstantatos A. PF0713 produced rapid induction of general anesthesia without injection pain in a phase 1 study [abstract]. In: Proceedings of the American Society of Anesthesiologists 2009 Annual Meeting; 2009 Oct 17-21; New Orleans, LA. Schaumburg (IL); ASA 2009; Astract nr 463. Available at: http:\/\/www.asaabstracts.com\/strands\/asaabstracts\/abstract.htm;jsessionid=F59BA4DFDCACB50816CB8DC9B572E45C?year=2009&index=7&absnum=841."},{"key":"10.1016\/j.anclin.2017.01.017_bib6","unstructured":"Siegel LC, Pecl LR, Dose SK. Dose response of PF0713, a novel investigational intravenous anesthesic [abstract[. In: Proceedings of the American Society of Anesthesiologists Annual Meeting; 2008, Oct 17-22; Orlando, FL. Schamburg (IL); ASA; 2008; Abstract nr 463. Available at: http:\/\/www.asaabstracts.com\/strands\/asaabstracts\/abstract.htm;jsessionid=7AF1B4F71FE3F8AE0E8C2680BF068EC5?year=2008&index=2&absnum=1096."},{"issue":"7","key":"10.1016\/j.anclin.2017.01.017_bib7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2036.2008.03598.x","article-title":"Clinical trial: a dose\u2013response study of fospropofol disodium for moderate sedation during colonoscopy","volume":"27","author":"Cohen","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.anclin.2017.01.017_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1378\/chest.08-0623","article-title":"A\u00a0phase 3, randomized, double-blind study to assess the efficacy and safety of fospropofol disodium injection for moderate sedation in patients undergoing flexible bronchoscopy","volume":"135","author":"Silvestri","year":"2009","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.anclin.2017.01.017_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MCG.0b013e3181c2987e","article-title":"A\u00a0randomized, double-blind, phase 3 study of fospropofol disodium for sedation during colonoscopy","volume":"44","author":"Cohen","year":"2010","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.anclin.2017.01.017_bib10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jclinane.2009.08.007","article-title":"Safety evaluation of fospropofol for sedation during minor surgical procedures","volume":"22","author":"Gan","year":"2010","journal-title":"J\u00a0Clin Anesth"},{"issue":"5","key":"10.1016\/j.anclin.2017.01.017_bib11","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1053\/j.jvca.2013.01.029","article-title":"A\u00a0randomized open-label phase I pilot study of the safety and efficacy of total intravenous anesthesia with fospropofol for coronary artery bypass graft surgery","volume":"27","author":"Fechner","year":"2013","journal-title":"J\u00a0Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.anclin.2017.01.017_bib12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/ALN.0b013e3181ae63d1","article-title":"Methoxycarbonyl- etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression","volume":"111","author":"Cotten","year":"2009","journal-title":"Anesthesiology"},{"issue":"4","key":"10.1016\/j.anclin.2017.01.017_bib13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/ALN.0b013e31821950de","article-title":"Closed-loop continuous infusions of etomidate and etomidate analogs in rats: a comparative study of dosing and the impact on adrenocortical function","volume":"115","author":"Cotten","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.anclin.2017.01.017_bib14","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/ALN.0b013e3182515403","article-title":"Electroencephalographic recovery, hypnotic emergence, and the effects of metabolite after continuous infusions of a rapidly metabolized eomidate analog in rats","volume":"116","author":"Pejo","year":"2012","journal-title":"Anesthesiology"},{"issue":"5","key":"10.1016\/j.anclin.2017.01.017_bib15","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/ALN.0b013e31826d3bef","article-title":"Modifying methoxycarbonyl etomidate inter-ester spacer optimizes in\u00a0vitro metabolic stability and in\u00a0vivo hypnotic potency and duration of action","volume":"117","author":"Husain","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.anclin.2017.01.017_bib16","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/ALN.0b013e31826d3de2","article-title":"Encephalographic and hypnotic recoveries following brief and prolonged infusions of etomidate and optimized soft etomidate analogs","volume":"117","author":"Ge","year":"2012","journal-title":"Anesthesiology"},{"issue":"6","key":"10.1016\/j.anclin.2017.01.017_bib17","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/ALN.0000000000000416","article-title":"Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs","volume":"121","author":"Campagna","year":"2014","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.anclin.2017.01.017_bib18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/ALN.0000000000000721","article-title":"Cyclopropyl-methoxycarbonyl metomidate: studies in a lipopolysaccharide inflammatory model of sepsis","volume":"123","author":"Santer","year":"2015","journal-title":"Anesthesiology"},{"key":"10.1016\/j.anclin.2017.01.017_bib19","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/ALN.0b013e3181cf40ed","article-title":"Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function","volume":"112","author":"Cotten","year":"2010","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.anclin.2017.01.017_bib20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CCM.0b013e31822d7924","article-title":"Differential effects of etomidate and its pyrrole analogue carboetomidate on the adrenocortical and cytokine responses to endotoxemia","volume":"40","author":"Pejo","year":"2012","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.anclin.2017.01.017_bib21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1213\/ANE.0b013e31827d204d","article-title":"The pyrrole etomidate analog carboetomidate potently inhibits human 5-HT3A receptor function: comparisons with etomidate and potential implications for emetogenesis","volume":"116","author":"Desai","year":"2013","journal-title":"Anesth Analg"},{"issue":"2","key":"10.1016\/j.anclin.2017.01.017_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1213\/ANE.0b013e3182320559","article-title":"In\u00a0vivo and in\u00a0vitro pharmacological studies of methoxycarbonyl-carboetomidate","volume":"115","author":"Pejo","year":"2012","journal-title":"Anesth Analg"},{"key":"10.1016\/j.anclin.2017.01.017_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/01.anes.0000267503.85085.c0","article-title":"CNS 7056: a novel ultra-short-acting benzodiazepine","volume":"107","author":"Kilpatrick","year":"2007","journal-title":"Anesthesiology"},{"key":"10.1016\/j.anclin.2017.01.017_bib24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1213\/ANE.0b013e31823f0c28","article-title":"A\u00a0placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part I. Safety, efficacy, and basic pharmacokinetics","volume":"115","author":"Antonik","year":"2012","journal-title":"Anesth Analg"},{"key":"10.1016\/j.anclin.2017.01.017_bib25","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1213\/ANE.0b013e318241f68a","article-title":"A\u00a0placebo and midazolam-controlled phase I single ascending dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056). Part II: population pharmacokinetic and pharmacodynamic modeling and simulation","volume":"115","author":"Wiltshire","year":"2012","journal-title":"Anesth Analg"},{"key":"10.1016\/j.anclin.2017.01.017_bib26","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1213\/ANE.0b013e3182a705ae","article-title":"A\u00a0phase Ib, dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy","volume":"117","author":"Worthington","year":"2013","journal-title":"Anesth Analg"},{"key":"10.1016\/j.anclin.2017.01.017_bib27","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1213\/ANE.0000000000000548","article-title":"A\u00a0phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy","volume":"120","author":"Borkett","year":"2015","journal-title":"Anesth Analg"},{"issue":"3","key":"10.1016\/j.anclin.2017.01.017_bib28","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1213\/ane.0b013e318193678f","article-title":"The antinociceptive effects and pharmacological properties of JM-1232(-): a novel isoindoline derivative","volume":"108","author":"Chiba","year":"2009","journal-title":"Anesth Analg"},{"issue":"2","key":"10.1016\/j.anclin.2017.01.017_bib29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/ALN.0b013e318242b2af","article-title":"First human administration of MR04A3: a novel water-soluble nonbenzodiazepine sedative","volume":"116","author":"Sneyd","year":"2012","journal-title":"Anesthesiology"},{"issue":"4","key":"10.1016\/j.anclin.2017.01.017_bib30","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.pbb.2008.05.011","article-title":"Effects of norketamine enantiomers in rodent models of persistent pain","volume":"90","author":"Holtman","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"10.1016\/j.anclin.2017.01.017_bib31","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1213\/ANE.0000000000000719","article-title":"Development of rapidly metabolized and ultra-short-acting ketamine analogs","volume":"121","author":"Harvey","year":"2015","journal-title":"Anesth Analg"},{"key":"10.1016\/j.anclin.2017.01.017_bib32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3109\/15563650.2014.892605","article-title":"Three months of methoxetamine administration is associated with significant bladder and renal toxicity in mice","volume":"52","author":"Dargan","year":"2014","journal-title":"Clin Toxicol"},{"issue":"14","key":"10.1016\/j.anclin.2017.01.017_bib33","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1080\/00397911.2014.885053","article-title":"Synthesis of 2-(2-fluorophenyl)-2-methylamino-cyclohexanone as a new ketamine derivative","volume":"44","author":"Moghimia","year":"2014","journal-title":"Synth Commun"},{"issue":"3","key":"10.1016\/j.anclin.2017.01.017_bib34","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/ALN.0000000000000044","article-title":"A\u00a0phase I, dose-escalation trial evaluating the safety and efficacy of emulsified isoflurane in healthy human volunteers","volume":"120","author":"Huang","year":"2014","journal-title":"Anesthesiology"},{"issue":"5","key":"10.1016\/j.anclin.2017.01.017_bib35","first-page":"1183","article-title":"Effects of intravenous bolus injection of emulsified isoflurane on QTc interval of healthy volunteers in pharmacokinetics study","volume":"27","author":"Liu","year":"2014","journal-title":"Pak J Pharm Sci"},{"issue":"5","key":"10.1016\/j.anclin.2017.01.017_bib36","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1097\/00000542-200411000-00016","article-title":"Intravenous emulsified halogenated anesthetics produce acute and delayed preconditioning against myocardial infarction in rabbits","volume":"101","author":"Chiari","year":"2004","journal-title":"Anesthesiology"},{"issue":"3","key":"10.1016\/j.anclin.2017.01.017_bib37","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1213\/ANE.0000000000001070","article-title":"The effectiveness and stability of a 20% emulsified sevoflurane formulation for intravenous use in rats","volume":"122","author":"Morohashi","year":"2016","journal-title":"Anesth Analg"},{"issue":"3","key":"10.1016\/j.anclin.2017.01.017_bib38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/vaa.12317","article-title":"General anesthesia with an injectable 8% v\/v sevoflurane lipid emulsion administered intravenously to dogs","volume":"43","author":"Natalini","year":"2016","journal-title":"Vet Anaesth Analg"},{"issue":"4","key":"10.1016\/j.anclin.2017.01.017_bib39","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1248\/bpb.17.514","article-title":"The potent depressant effects of N3-phenacyluridine in mice","volume":"17","author":"Yamamoto","year":"1994","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"10.1016\/j.anclin.2017.01.017_bib40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/004982500406462","article-title":"Metabolism of a novel hypnotic, N3-phenacyluridine, and hypnotic and sedative activities of its enantiomer metabolites in mouse","volume":"30","author":"Kimura","year":"2000","journal-title":"Xenobiotica"},{"key":"10.1016\/j.anclin.2017.01.017_bib41","first-page":"57","article-title":"N3-phenacyluridine as a new type of antinociceptive compound in mice","volume":"113\u2013114","author":"Kimura","year":"2003","journal-title":"Res Commun Mol Pathol Pharmacol"},{"issue":"4","key":"10.1016\/j.anclin.2017.01.017_bib42","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1213\/ANE.0000000000000831","article-title":"First human study of the investigational sedative and anesthetic drug AZD3043: a dose-escalation trial to assess the safety, pharmacokinetics, and efficacy of a 30-minute infusion in healthy male volunteers","volume":"121","author":"Kalman","year":"2015","journal-title":"Anesth Analg"},{"issue":"4","key":"10.1016\/j.anclin.2017.01.017_bib43","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1213\/ANE.0000000000000804","article-title":"A\u00a0bolus and bolus followed by infusion study of AZD3043, an investigational intravenous drug for sedation and anesthesia: safety and pharmacodynamics in healthy male and female volunteers","volume":"121","author":"Norberg","year":"2015","journal-title":"Anesth Analg"},{"key":"10.1016\/j.anclin.2017.01.017_bib44","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4103\/0976-500X.99457","article-title":"Fospropofol","volume":"3","author":"Mahajan","year":"2012","journal-title":"J\u00a0Pharmacol Pharmacother"},{"key":"10.1016\/j.anclin.2017.01.017_bib45","series-title":"U.S. Food and Drug Administration. Drug approval package: lusedra (fospropofol disodium) injection","year":"2009"},{"key":"10.1016\/j.anclin.2017.01.017_bib46","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1213\/ane.0b013e31818ce924","article-title":"Fospropofol assay issues and impact on pharmacokinetic and pharmacodynamic evaluation","volume":"108","author":"Shah","year":"2009","journal-title":"Anesth Analg"},{"key":"10.1016\/j.anclin.2017.01.017_bib47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/EJA.0b013e32831bc285","article-title":"Fospropofol assay issues and impact on pharmacokinetic and pharmacodynamic evaluation","volume":"26","author":"Shah","year":"2009","journal-title":"Eur J Anaesthesiol"},{"issue":"2","key":"10.1016\/j.anclin.2017.01.017_bib48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/CNQ.0000000000000012","article-title":"Remifentanil, ketamine, and fospropofol: a review of alterative continuous infusion agents for sedation in the critically ill","volume":"37","author":"Mohrien","year":"2014","journal-title":"Crit Care Nurs Q"},{"issue":"4","key":"10.1016\/j.anclin.2017.01.017_bib49","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1213\/ANE.0000000000000124","article-title":"An improved design of water-soluble propofol prodrugs characterized by rapid onset of action","volume":"118","author":"Lang","year":"2014","journal-title":"Anesth Analg"},{"key":"10.1016\/j.anclin.2017.01.017_bib50","unstructured":"Clinicaltrials.gov: A service of the U.S. National Institutes of Health. Available at: https:\/\/clinicaltrials.gov\/ct2\/results?term=remimazolam&Search=Search. Accessed June 20, 2016."},{"key":"10.1016\/j.anclin.2017.01.017_bib51","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1248\/cpb.55.1682","article-title":"Novel water-soluble sedative-hypnotic agents: isoindolin-1-one derivatives","volume":"55","author":"Kanamitsu","year":"2007","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.anclin.2017.01.017_bib52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(97)01116-3","article-title":"Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord","volume":"333","author":"Ebert","year":"1997","journal-title":"Eur J Pharmacol"},{"issue":"17","key":"10.1016\/j.anclin.2017.01.017_bib53","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1016\/j.bmc.2013.06.047","article-title":"Structure-activity relationships for ketamine esters as short-acting anaesthetics","volume":"21","author":"Jose","year":"2013","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"10.1016\/j.anclin.2017.01.017_bib54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hup.1242","article-title":"Phenomenon of new drugs on the internet: the case of ketamine derivative methoxetamine","volume":"27","author":"Corazza","year":"2012","journal-title":"Hum Psychopharmacol"},{"issue":"1","key":"10.1016\/j.anclin.2017.01.017_bib55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13181-011-0202-2","article-title":"Here today, gone tomorrow\u2026 and back again? A review of herbal marijuana alter- natives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines","volume":"8","author":"Rosenbaum","year":"2012","journal-title":"J\u00a0Med Toxicol"},{"key":"10.1016\/j.anclin.2017.01.017_bib56","unstructured":"National Center for Biotechnology Information, PubChem: Open Chemistry Database. Available at: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/13771618#section=WIPO-IPC. Accessed June 20, 2016."},{"key":"10.1016\/j.anclin.2017.01.017_bib57","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1213\/00000539-199205000-00021","article-title":"Acute pulmonary edema after intravenous liquid halothane in dogs","volume":"74","author":"Kawamoto","year":"1992","journal-title":"Anesth Analg"},{"key":"10.1016\/j.anclin.2017.01.017_bib58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF03028273","article-title":"Anaesthesia by intravenous emulsified isoflurane in mice","volume":"42","author":"Eger","year":"1995","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.anclin.2017.01.017_bib59","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1213\/01.ane.0000189612.24147.07","article-title":"The efficacy and safety of intravenous emulsified isoflurane in rats","volume":"102","author":"Zhou","year":"2006","journal-title":"Anesth Analg"},{"key":"10.1016\/j.anclin.2017.01.017_bib60","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/00000542-200603000-00015","article-title":"Comparison of minimum alveolar concentration between intravenous isoflurane lipid emulsion and inhaled isoflurane in dogs","volume":"104","author":"Yang","year":"2006","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.anclin.2017.01.017_bib61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/vaa.12287","article-title":"Comparison of the effects of propofol and emulsified isoflurane alone or combined with dexmedetomidine on induction of anesthesia in dogs","volume":"43","author":"Diao","year":"2016","journal-title":"Vet Anaesth Analg"},{"issue":"5","key":"10.1016\/j.anclin.2017.01.017_bib62","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1213\/ANE.0000000000001172","article-title":"Emulsified isoflurane protects against transient focal cerebral ischemia injury in rats via the PI3K\/Akt signaling pathway","volume":"122","author":"Zhang","year":"2016","journal-title":"Anesth Analg"},{"issue":"4","key":"10.1016\/j.anclin.2017.01.017_bib63","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12576-013-0261-z","article-title":"Emulsified isoflurane postconditioning produces cardioprotection against myocardial ischemia-reperfusion injury in rats","volume":"63","author":"Hu","year":"2013","journal-title":"J\u00a0Physiol Sci"},{"issue":"2","key":"10.1016\/j.anclin.2017.01.017_bib64","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1213\/ANE.0b013e31821e9797","article-title":"The interaction between emulsified isoflurane and lidocaine is synergism in intravenous regional anesthesia in rats","volume":"113","author":"Zhou","year":"2011","journal-title":"Anesth Analg"},{"key":"10.1016\/j.anclin.2017.01.017_bib65","first-page":"235","article-title":"Adding emulsified isoflurane to cardioplegia solution produces cardiac protection in a dog cardiopulmonary bypass model","volume":"6","author":"Huang","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.anclin.2017.01.017_bib66","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/ALN.0b013e3182475d4d","article-title":"Exceptionally stable fluorous emulsions for the intravenous delivery of volatile general anesthetics","volume":"116","author":"Jee","year":"2012","journal-title":"Anesthesiology"},{"issue":"4","key":"10.1016\/j.anclin.2017.01.017_bib67","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/ALN.0b013e31818630ff","article-title":"Fluoropolymer-based emulsions for the intravenous delivery of sevoflurane","volume":"109","author":"Fast","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.anclin.2017.01.017_bib68","unstructured":"Druzgala P, Milner PG. Inventors; ARYx Therapeutics, Inc., assignee. Ultrashort acting hypnotic barbiturates. US Patent 6,387,914 B2. May 14, 2002."},{"key":"10.1016\/j.anclin.2017.01.017_bib69","unstructured":"Druzgala P, Milner PG. Inventors; ARYx Therapeutics, Inc., assignee. Ultrashort acting hypnotic barbiturates. US Patent RE41, 289 E. April 27, 2010."},{"key":"10.1016\/j.anclin.2017.01.017_bib70","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0022-3565(25)31447-3","article-title":"Effects of natural pyrimidines and of certain related compounds on the spontaneous activity of the mouse","volume":"207","author":"Krooth","year":"1978","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.anclin.2017.01.017_bib71","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0006-8993(73)90296-5","article-title":"Anticonvulsant effects of uridine: comparative analysis of metrazol and penicillin induced foci","volume":"55","author":"Roberts","year":"1973","journal-title":"Brain Res"},{"key":"10.1016\/j.anclin.2017.01.017_bib72","first-page":"223","article-title":"Uridine, a sleep-promoting substance from brainstems of sleep-deprived rats","volume":"4","author":"Komoda","year":"1983","journal-title":"Biomed Res"},{"key":"10.1016\/j.anclin.2017.01.017_bib73","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0168-0102(84)80003-6","article-title":"Uridine as an active component of sleep-promoting substance: its effects on nocturnal sleep in rats","volume":"1","author":"Honda","year":"1984","journal-title":"Neurosci Res"},{"key":"10.1016\/j.anclin.2017.01.017_bib74","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.1073\/pnas.81.19.6240","article-title":"Differential sleep promoting effects of five sleep substances nocturnally infused in unrestrained rats","volume":"81","author":"Inoue","year":"1984","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"10","key":"10.1016\/j.anclin.2017.01.017_bib75","first-page":"1027","article-title":"A\u00a0new steroid anaesthetic\u2014althesin","volume":"66","author":"Clarke","year":"1973","journal-title":"Proc R\u00a0Soc Med"},{"key":"10.1016\/j.anclin.2017.01.017_bib76","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/01.aco.0000236137.23475.95","article-title":"Drug development in anaesthesia: industrial perspective","volume":"19","author":"Kilpatrick","year":"2006","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1016\/j.anclin.2017.01.017_bib77","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s001010050191","article-title":"Anesthesia with propanidid in a liposomal preparation: an experimental study in swine","volume":"44","author":"Klockgether-Radke","year":"1995","journal-title":"Anaesthesist"},{"issue":"1","key":"10.1016\/j.anclin.2017.01.017_bib78","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.anclin.2017.01.017_bib79","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J\u00a0Health Econ"}],"container-title":["Anesthesiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1932227517300228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1932227517300228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T22:26:54Z","timestamp":1750199214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1932227517300228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1932227517300228"],"URL":"https:\/\/doi.org\/10.1016\/j.anclin.2017.01.017","relation":{},"ISSN":["1932-2275"],"issn-type":[{"value":"1932-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Hypnotic Drug Development and Pharmacologic Considerations for Clinical Anesthesia","name":"articletitle","label":"Article Title"},{"value":"Anesthesiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anclin.2017.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}